Prostate Cancer Active Surveillance Increasing in the US
From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.
From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
Almac Diagnostics has published analytical validation of a 70-gene assay designed for use with formalin-fixed paraffin-embedded samples.
Biomarkers of PD-1/PD-L1 checkpoint inhibitor response in prostate cancer could help stratify patients by response.
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
In a Spanish study, the highest vs lowest tertile of dietary zinc intake was associated with a significant 66% increased relative risk of low-grade prostate cancer.
Statin use by men receiving androgen deprivation therapy for advanced PCa was associated with decreased risk of overall and cancer-specific mortality.
A study suggests HIMRT may have some advantages over CIMRT for treating men with localized prostate cancer.
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.